Drugmakers Seek Review of Intervention in HHS Rebate Pilot Suit

March 23, 2026, 4:55 PM UTC

Major drugmakers are asking a federal appeals court to reverse an order that denied them from intervening in a case now closed between hospitals groups and the US government over a federal drug rebate pilot program.

The request from AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim Pharmaceuticals Inc., Novo Nordisk A/S, and the Pharmaceutical Research and Manufacturers of America asks the US Court of Appeals for the First Circuit to hear why they should have intervened in a case brought by the American Hospital Association against the Department of Health and Human Services’ 340B Rebate Model Pilot ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.